iFactory Inc.

Located in Japan, iFactory Inc. focuses on developing innovative modular continuous manufacturing systems for functional chemicals, emphasizing energy efficiency and automation in production processes. iFactory Inc. was established in 2019 in Tokyo, Japan, specializing in advanced manufacturing systems.

The company has undergone a strategic pivot to emphasize modular production capabilities. It raised JPY 1 billion in Series A funding on October 30, 2025, with investments from Globis Capital Partners and SBI Investment, bringing the total amount raised to JPY 1 billion. iFactory, Inc. specializes in advanced modular continuous manufacturing systems for functional chemicals, focusing on energy efficiency and automation.

Their flagship product, the iFactory®, integrates multiple operations—such as reaction, extraction, crystallization, filtration, and drying—into a modular framework for flexible and scalable manufacturing. Released in 2023, the iFactory® optimizes production workflows and reduces operational costs for industries needing efficient chemical synthesis. Additionally, the company offers the iFactory Trigger™, a lab-scale model producing up to 300 grams of chemicals per hour for research and small-scale production. iFactory's products target chemical manufacturers in regions including North America, Europe, and Asia, serving clients from pharmaceuticals to specialty chemicals.

Revenue for iFactory, Inc. is derived from the sale of its modular manufacturing systems, along with service agreements for installation and maintenance. The company primarily engages in B2B sales, focusing on established chemical manufacturers and research facilities. Clients directly purchase the iFactory® and Trigger systems based on specific needs, with ongoing support and maintenance services forming a reliable revenue stream.

Contracts are tailored to align with each client's manufacturing requirements, reinforcing iFactory's position in the continuous manufacturing sector. In October 2025, iFactory Inc. secured JPY 1 billion in Series A funding, which will be utilized to enhance its demonstration facilities, improve its human resources framework, and expedite the development of a system for mass production, assembly, and service delivery. The company is also planning to expand its product offerings with new innovations and aims to penetrate additional markets beyond its existing regions by 2026.